Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01567163 · ClinicalTrials.gov registry record · Phase 2
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01567163 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 22 participants.
The verdict
NCT01567163, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in participants with advanced malignant solid tumors. Participants who do not complete both Cycle 1, Day 1, and Cycle 2, Day 1 according to schedule will be replaced for the purpose of analysis; these participants may continue to receive study therapy. No dose reductions, delayed or missed doses are allowed during Cycles 1 and 2.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01567163
The ClinicalTrials.gov registry entry for NCT01567163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01567163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01567163 about?
NCT01567163 is a clinical study titled "A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors". The purpose of this study is to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in participants with advanced malignant solid tumors. Participants who do not complete both Cycle 1, Day 1, and Cycle 2, Day 1 according to schedule will be replaced for the purpose of ...
What is the current status of trial NCT01567163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2012-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01567163?
The interventions under investigation include: Docetaxel (DRUG), Ramucirumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01567163?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.